The Cooper Health System
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus. The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.
Inclusion Criteria: * Age 18 years or older * Diagnosis of hematological malignancy * Treatment with HSCT or CAR-T therapy * Must be able to give informed consent * Must be willing to provide blood samples after HSCT or CAR-T therapy and prior to vaccination * Must be willing to provide blood samples at four weeks and six months post-vaccination * Must have an insurance plan that covers the cost of recieving the RSV vaccine. Exclusion Criteria: * History of a severe allergic reaction to any component of the RSV vaccine * Use of intravenous immunoglobulin (IVIG) for hypogammaglobulinemia wit…
Patients will receive a single dose of the Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) starting at three months post-HSCT or CAR-T therapy.
Arctuva estimate
Verify or correct the compensation shown for this listing.